Navigation Links
2-step ovarian cancer immunotherapy made from patients' own tumor shows promise
Date:4/6/2013

WASHINGTON, D.C. As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach -- including one patient who achieved complete remission -- according research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today in a press conference at the AACR Annual Meeting 2013 (Presentation #LB-335).

The immunotherapy has two steps a personalized dendritic cell vaccination and adoptive T-cell therapy. The team reports that in the study of 31 patients, vaccination therapy alone showed about a 61 percent clinical benefit, and the combination of both therapies showed about a 75 percent benefit.

The findings offer new hope for the large number of ovarian cancer patients who relapse following treatment. The first step of the immunotherapy approach is to preserve the patient's tumor cells alive, using sterile techniques at the time of surgery so they can be used to manufacture a personalized vaccine that teaches the patient's own immune system to attack the tumor. Then, the Penn Medicine team isolates immune cells called dendritic cells from patients' blood through a process called apheresis, which is similar to the process used for blood donation. Researchers then prepare each patient's personalized vaccine by exposing her dendritic cells to the tumor tissue that was collected during surgery.

Because ovarian cancer symptoms can be stealth and easily mistaken for other issues constipation, weight gain, bloating, or more frequent urination more than 60 percent of patients are diagnosed only after the disease has spread to their lymph nodes or other distant sites in the body, when treatment is much less likely to produce a cure compared to when the disease is detected early. As the fifth leading cause of cancer-related deaths among women in the United States, it takes the lives of more than 14,000 women each year.

"Given these grim outcomes, there is definitely a vast unmet need for the development of novel, alternate therapies," said lead author Lana Kandalaft, PharmD, PhD, MTR, a research assistant professor of Obstetrics and Gynecology and director of clinical development and operations in Penn Medicine's Ovarian Cancer Research Center. "This is the first time such a combination immunotherapy approach has been used for patients with ovarian cancer, and we believe the results are leading us toward a completely new way to treat this disease."

Both treatments are given in conjunction with bevacizumab, a drug that controls the blood vessel growth that feeds tumors. Combining bevacizumab with immunotherapy makes a powerful duo, Kandalaft says. The vaccine trial is still open to accrual to test new combinatorial strategies.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. 12-Step Meetings May Help Teens Beat Alcohol, Drug Abuse
2. 2-step immunotherapy attacks advanced ovarian cancer
3. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
4. U.S. Panel Rejects Ovarian Cancer Screening
5. UC Irvine study finds racial, economic disparities in ovarian cancer care, survival
6. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
7. The prevention of hereditary breast and ovarian cancer by PGD is feasible
8. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
9. Ovarian Transplants May Preserve Fertility in Young Cancer Survivors
10. Benefit of PET and PET/CT in ovarian cancer is not proven
11. Mechanisms of acquired chemoresistance in ovarian cancer identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... and London UK (PRWEB) , ... June 27, 2017 , ... ... to a clinical study is whether they can trust the sponsor to pay them ... is vital that sponsors and CROs establish payment strategies that encourage sites to work ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... payment solution for many of the health care industry’s hospitals and provider groups, ... patient financing portal for select customers. Parasail Health is a San Francisco health-finance ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building ... SUNucate efforts, Louisiana became the sixth state to pass legislation which ensures that ... Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, Utah and ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... A January ... been projected to reach a staggering $6.81 billion by the year 2024 according to ... at a faster rate than those made from titanium. Los Angeles area clinic Beverly ...
(Date:6/27/2017)... ... 2017 , ... The Kelahan Agency, a privately owned firm ... southern New Hampshire, is teaming up with the New Horizons for New Hampshire ... the region. , New Horizons for New Hampshire provides a wealth of services ...
Breaking Medicine News(10 mins):
(Date:5/29/2017)... TEL AVIV, Israel, May 29, 2017  Cellect Biotechnology ... of innovative technology which enables the functional selection of ... financial results for the first quarter ended March 31 ... pleased with our accomplishments in the first quarter of ... the first quarter, we announced the treatment of the ...
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, recognized ... medical devices for pressure ulcer prevention, will unveil ... Association of Critical Care Nurses, National Teaching Institute ... The Leaf Patient Monitoring System is ... the hospital environment.  The system seamlessly tracks patient ...
Breaking Medicine Technology: